Search

Povidone-iodine is identified as one of the widely applicable antiseptic reagents for treatment of skin infection and wound healing. Controllable releasing of povidone-iodine is extensively required for healing of chronic wounds. The release of povidone-iodine was systematically studied from the composites based on carboxymethyl starch (CMS). Currently, different ratios from copper precursor and L-aspartic acid (L-AA) were interacted with CMS to obtain Cu-L-AA@CMS composites. Increment the percentage of L-AA was reflected in clustering of dense masses from the desirable composite with highly crystalline/stable structural network. Regardless to pH conditions, Cu-L-AA(30%)@CMS composite showed the highest efficiency for controllable release of povidone-iodine, whereas, the release percentages were estimated to be 58%, 32% and 18% at pH 5, 7 and 9, respectively. The kinetic results revealed the impossibility of povidone-iodine releasing via diffusion/erosion for further support of the hypothesis of releasing via swelling process. Moreover, the release of povidone-iodine using column technique showed that the lowest release was estimated at using high rate of 6 mL/min. Besides the biocompatibility and biodegradability of the prepared Cu-L-AA@CMS composites, it showed the superiority for controllable release of povidone-iodine antiseptic reagent to regulate its beneficial effect in curing of the skin. [ABSTRACT FROM AUTHOR]

The chemokine receptor CXCR4 is implicated in multiple diseases including inflammatory disorders, cancer growth and metastasis, and HIV/AIDS. CXCR4 targeting has been evaluated in treating cancer metastasis and therapy resistance. Cyclam derivatives, most notably AMD3100 (Plerixafor™), are a common motif in small molecule CXCR4 antagonists. However, AMD3100 has not been shown to be effective in cancer treatment as an individual agent. Configurational restriction and transition metal complex formation increases receptor binding affinity and residence time. In the present study, we have synthesized novel trans-IV locked cyclam-based CXCR4 inhibitors, a previously unexploited configuration, and demonstrated their higher affinity for CXCR4 binding and CXCL12-mediated signaling inhibition compared to AMD3100. These results pave the way for even more potent CXCR4 inhibitors that may provide significant efficacy in cancer therapy. [ABSTRACT FROM AUTHOR]

[Display omitted] • M(Co & Ni)-BTC@wool composites were synthesized in one-pot process. • Adsorption of sulfamethazine and sulfanilamide onto M(Co & Ni)-BTC@wool was studied. • Maximum capacity of sulfamethazine and sulfanilamide was 420.38 and 292.44 mg/g onto Ni-BTC@wool. • Insertion of Ni-BTC improved the maximum capacities of wool by 1.77 – 1.92 times. • After 6 recycles, adsorption capacity was diminished by 11.3 – 15.9% only. Antibiotics are widely used to treat different infections, and consequently they are discharged in the wastewater after human desecration, causing pollution of aquatic system. Therefore, the current study focused on removal of sulfa drugs as broad spectrum antibiotics from water by metal (Co & Ni)-benzene tricarboxylic acid (M−BTC) incorporated within wool. M (Co & Ni)-BTC was synthesized and incorporated within wool network matrix in one-pot process. The obtained M−BTC@wool composites were exploited in the removal of two different sulfa drugs namely; sulfamethazine and sulphanilamide. Adsorption of both of sulfa drugs onto composites was kinetically followed the pseudo-second order and Langmuir isotherm model. M−BTC@wool composites showed higher affinity towards sulfamethazine rather than sulphanilamide. The maximum Langmuir capacities of Co-BTC@wool and Ni-BTC@wool composites were 360.21 & 420.38 mg/g for sulfamethazine and 239.25 & 292.44 mg/g for sulphanilamide, respectively. By incorporation of Ni-BTC within wool, the adsorption capacity of sulfamethazine and sulphanilamide was enlarged by factor of 1.77 and 1.92, respectively. The applied composites were exhibited with quite good reusability and their efficiency in the removal of sulfamethazine and sulphanilamide was decreased by only 14.8 – 15.9 % and 11.3 – 12.7 %, respectively, after six consecutive adsorption cycles. [ABSTRACT FROM AUTHOR]

In the last two decades, poultry and animal industries became increasingly interested in using plant‐based feed supplements, herbs and their derivatives to retain or enhance their health and productivity. These health benefits for the host mainly attributed to the secondary plant metabolites, namely polyphenols. Polyphenols are renowned for their antioxidant, immunomodulatory, anti‐mutagenic and anti‐inflammatory properties. However, despite these advantages of polyphenols, they have been characterized by poor absorption in the gut and low concentration in target cells that compromise their role as effective antioxidants. The low bioavailability of polyphenols necessitates the need for further investigations to harness their full potential in poultry farms. This review is existing evidence about the bioavailability of polyphenols and their antioxidant, immunomodulatory, antimicrobial, detoxification properties and their impacts on poultry performance. [ABSTRACT FROM AUTHOR]

The unsymmetrical tetradentate ONNO Schiff base 6,6'-((1E,1'E)-((2-methylpropane-1,2-diyl)bis(azanylylidene))bis(methanylylidene))bis(2,4-di-tert-butylphenol) (H2L) was prepared following a slightly modified known condensation reaction. The neutral NiL complex has been synthesized in high yield via [1H2L:1Ni(II)] direct addition. The XRD-measurement reflects a NiII center with slightly distorted square planar geometry. Moreover, the lattice is stabilized by a number of H-bond and H...π stacking interactions. The structure connections have been illustrated by electrostatic potential surface (Molecular Electrostatic Potential, MEP) and Hirschfeld surface (HSA) and Fingerprint (FP) analysis to support such interactions. IR and UV-visible spectra were measured to compare free H2L with NiL behaviors. The DFT-optimized structure was compared to the XRD-structure parameters. NiL reflects high thermal stability and decomposed mainly via one-step to form NiO as the final product. [ABSTRACT FROM AUTHOR]

• Synthesized Schiff base complexes were studied by available tools. • A conductometry study was carried out in order to extract important parameters. • In vitro tests were performed on bacteria, fungus, free radicals, and cancer cell lines. • To strengthen the study, extensive theoretical implementations were carried out. Ball milling was used to obtain new Schiff-base complexes from Co(II), Fe(III), Ni(II), and Zn(II) ions in their solid form, which is considered a green method of preparation. Several spectroscopic (IR, UV–Vis, 1H NMR, Mass, SEM, EDX, XRD) and analytical approaches were used to suggest the geometries of isolated compounds. Coats–Redfern and Horowitz–Metzger methods were used to compute the kinetic and thermodynamic parameters of Zn(II) complex (i.e.). Furthermore, conductometry was used to estimate both formation/association constants of Co(II) complex (i.e.) in solution at 290.15 K. The feature of the complex in solution may offer a good view about it in its solid state. Standard methods were applied to test the antibacterial activity of ligand and complexes to TOS aureus, E. coli and Candida albicans fungus. To assess their inhibitory effect, ABTS-antioxidant screening and cytotoxicity against liver cancer cells (HepG2) were also performed. Most complexes showed mild to considerable activity towards the selected microorganisms and liver cancer cell line, respectively. The structural forms were optimized using molecular modeling, which then confirmed the binding mechanism provided by spectral analyses. To investigate the degree of inhibition for new drugs versus three selected proteins (1dee, 5uw2 and 7jx9), two in-silico techniques were used: Pharmit link and Molecular Operating Environmental module (MOE, vs 2018). The docking patterns as well as the interaction data were acquired and analyzed. The high consistency of in-vitro and in-silico outcomes lends credence to computational treatments that must be done on developed medications before they can be used in practice. [ABSTRACT FROM AUTHOR]

Two mononuclear M(II) complexes (M = Ni2+ and ZrO2+ cations) of the imino-naphthalenol sodium sulfonate ligand (H 2 Lig) were prepared and characterized via different physicochemical tools and DFT calculations. The interactions of the prepared complexes with DNA were explored. Furthermore, pharmaceutical studies on the prepared compounds were performed. [Display omitted] A green synthetic pathway for two mononuclear M(II)-complexes (M = Ni2+ as a non-oxy-metal ion and ZrO2+ as an oxy-metal ion, NiLig and ZrOLig, respectively) of an imino-naphthalenol sodium sulfonate ligand (H 2 Lig) was followed. Using various physico-chemical tools, their chemical compositions were elucidated. The material-studio package was applied to confirm the structures of NiLig and ZrOLig via the DFT method. The biological potential of the ligand (H 2 Lig) and its NiLig and ZrOLig complexes was investigated for different microbial strains as well as different cancer cell lines. The redox potential of the newly synthesized complexes was evaluated using different biochemical assays, e.g. DPPH and SOD assays. The NiLig and ZrOLig complexes exhibited improved antimicrobial and anticancer activities as compared to the free ligand (H 2 Lig). Accordingly, the ZrOLig complex was the most active biological reagent. The binding nature of the M2+ complexes to calf thymus DNA (ct DNA) was examined by UV–Vis. spectrophotometry and viscosity measurements. Both the Ni2+ and ZrO2+ complexes interestingly demonstrated anti-proliferative action against the human cancer cell lines. Such ct DNA interactions were examined theoretically by molecular docking. The approaches between the exported in-silico drug-likeness and the considered DNA interaction study were explored. The binding action between the M2+ complex and DNA would be within the electrostatic minor groove, intercalation and replacement binding modes. [ABSTRACT FROM AUTHOR]